With news leaking in the adult industry that at least two HIV+ people are in the talent pool, we have all started to look at ways to reduce the risk of getting HIV. Scientists may be one step closer to offering a solution.

A once-a-year injection designed to protect against HIV has successfully completed an important early-stage safety trial, offering hope for a long-acting alternative to daily pills and bi-monthly injections.

Published in The Lancet medical journal, the study showed that Lenacapavir, an antiviral drug that prevents HIV replication in human cells, remained detectable in trial participants more than a year after a single dose.

If further trials confirm its effectiveness and safety, Lenacapavir could become the longest-lasting pre-exposure prophylaxis (PrEP) treatment available, significantly reducing barriers to HIV prevention.

Currently, PrEP—which reduces the risk of contracting HIV—requires either a daily pill or an injection every two months. While these methods are highly effective, they can be challenging to maintain over time, particularly in high-risk populations with limited healthcare access.

Lenacapavir, an injectable capsid inhibitor, works by stopping HIV from replicating inside cells. Its long duration in the body means a single yearly injection could provide continuous protection—a significant advantage for people who struggle with daily medication adherence.

In this Phase I trial, 40 HIV-negative participants received one muscle injection of Lenacapavir, with no major side effects reported. After 56 weeks, researchers confirmed that the drug remained present in the bloodstream, indicating its potential long-term effectiveness.

Researchers emphasized the need for larger and more diverse trials, which will be conducted to further evaluate the drug’s efficacy and safety.

The Global HIV Challenge and the Push for Better Prevention
According to 2023 data, approximately 39.9 million people worldwide are living with HIV, with 65% of cases concentrated in the World Health Organization (WHO) African Region.

International organizations, including the WHO, Global Fund, and UNAIDS, have committed to ending the HIV epidemic by 2030, with improved access to PrEP playing a crucial role in this strategy.

HIV activists and medical experts have welcomed the trial results, emphasizing the game-changing potential of an annual PrEP injection.

“The prospect of a safe annual injectable PrEP is as exciting as it is transformational,” said Richard Angell of the Terrence Higgins Trust, a leading HIV charity.

“We need to get ready for its rollout now and fund sexual-health clinics to do so.”

Despite the promise of new HIV prevention methods, access to existing PrEP options remains unequal across different regions.

In England, two-monthly PrEP injections are still awaiting approval from the National Institute for Health and Care Excellence (NICE), while Scotland has already approved them.
Prisons, community pharmacies, and online health services still lack consistent PrEP access, leaving many vulnerable populations without crucial protection.

Angell urged health authorities to prioritize equitable access to new PrEP methods, ensuring that annual injections, when available, reach all communities in need.

The success of this early-stage trial is a crucial first step toward annual injectable HIV prevention. However, further research is needed to confirm its effectiveness in preventing infection before global health agencies approve it for widespread use.

If future trials continue to show strong safety and efficacy, Lenacapavir could mark a new era in HIV prevention, making it easier for millions worldwide to stay protected with a single yearly injection.

If you are an adult performer, remember to check the person’s test that you are working with. Don’t just take their word for it and only work with performers who test at companies that do the antibody test, like TTS.

If a person refuses to test with TTS (or says they can’t), you have to ask yourself why. Did they get caught faking a test? Or even worse, do they know that their HIV status will be exposed?

Either way, not worth the risk with someone who can’t or won’t test with TTS.

To those idiots who say HIV is no big deal and is the medication (ART), doctor visits, and lab monitoring (like CD4 counts and viral load tests) costs between $2,000 and $5,000 per month.

Then factor in the side effects, which include but are not limited to nausea and vomiting, fatigue, diarrhea, headaches, rash, problems sleeping, weight gain, lipodystrophy, blonde density loss, Immune Reconstitution Inflammatory Syndrome (IRIS), and even more serious, kidney and liver damage.

So yes, HIV is a very serious issue. Don’t let anyone tell you otherwise.

Please be careful out there and remember to always do your due diligence with anyone you sleep with. And most importantly, don’t just assume someone will be honest with you.